High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$17.1M
$17,088,027
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
TVTX
S
Travere Therapeutics, Inc.
Dube Eric M
• CEO
10b5-1 SellΔOwn -12.2%
2026-02-20
$1,805,766Large
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -12.2%
|
2026-02-20 | $1,805,766Large | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
REED ELIZABETH E
• Officer • Chief Legal Officer and GC
10b5-1 Sell
2026-02-17
$278,315x2
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • Chief Legal Officer and GC
10b5-1 Sell
|
2026-02-17 | $278,315x2 | S | Form 4 |
| TVTX |
Travere Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-02-04 | $56,168x2 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Inrig Jula
• Officer • CHIEF MEDICAL OFFICER
10b5-1 Sell
2026-02-04
$57,295x2
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 Sell
|
2026-02-04 | $57,295x2 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
REED ELIZABETH E
• Officer • Chief Legal Officer and GC
10b5-1 Sell
2026-02-04
$96,359x2
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • Chief Legal Officer and GC
10b5-1 Sell
|
2026-02-04 | $96,359x2 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
Sell to Cover
2026-02-03
$139,176
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
Sell to Cover
|
2026-02-03 | $139,176 | S | Form 4 |
| TVTX |
Travere Therapeutics, Inc.
|
CFO
Sell to Cover
|
2026-02-03 | $232,613 | S | Form 4 |
| TVTX |
Travere Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-02-03 | $3,230,316Largex2 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Heerma Peter
• Officer • CHIEF COMMERCIAL OFFICER
Sell to Cover
2026-02-03
$234,797
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • CHIEF COMMERCIAL OFFICER
Sell to Cover
|
2026-02-03 | $234,797 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Inrig Jula
• Officer • CHIEF MEDICAL OFFICER
Sell to Cover
2026-02-03
$223,427
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Sell to Cover
|
2026-02-03 | $223,427 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
REED ELIZABETH E
• Officer • Chief Legal Officer and GC
Sell to Cover
2026-02-03
$230,461
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • Chief Legal Officer and GC
Sell to Cover
|
2026-02-03 | $230,461 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
ROTE WILLIAM E.
• Officer • Chief Research Officer
10b5-1 SellΔOwn -10.2%
2026-02-03
$409,100
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • Chief Research Officer
10b5-1 SellΔOwn -10.2%
|
2026-02-03 | $409,100 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Dube Eric M
• CEO
10b5-1 SellΔOwn -11.0%
2026-01-27
$1,560,981Large
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -11.0%
|
2026-01-27 | $1,560,981Large | S | Form 4 |
| TVTX |
Travere Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-01-23 | $244,153 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
REED ELIZABETH E
• Officer • Chief Legal Officer and GC
10b5-1 Sell
2026-01-20
$273,420
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • Chief Legal Officer and GC
10b5-1 Sell
|
2026-01-20 | $273,420 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 Sell
2025-12-15
$104,760
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 Sell
|
2025-12-15 | $104,760 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Cline Christopher R.
• CFO
10b5-1 SellΔOwn -17.8%
2025-12-01
$700,202
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
CFO
10b5-1 SellΔOwn -17.8%
|
2025-12-01 | $700,202 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -58.0%
2025-11-04
$2,416,140Large
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -58.0%
|
2025-11-04 | $2,416,140Large | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Coughlin Timothy
• Director
10b5-1 SellΔOwn -24.5%
2025-10-31
$630,601
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Director
10b5-1 SellΔOwn -24.5%
|
2025-10-31 | $630,601 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Heerma Peter
• Officer • CHIEF COMMERCIAL OFFICER
10b5-1 Sell
2025-10-31
$195,685
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • CHIEF COMMERCIAL OFFICER
10b5-1 Sell
|
2025-10-31 | $195,685 | S | Form 4 |
| TVTX |
Travere Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-10-29 | $817,074 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Dube Eric M
• CEO
10b5-1 SellΔOwn -18.1%
2025-10-28
$2,821,358Large
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
CEO
10b5-1 SellΔOwn -18.1%
|
2025-10-28 | $2,821,358Large | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Heerma Peter
• Officer • CHIEF COMMERCIAL OFFICER
10b5-1 Sell
2025-10-28
$79,860
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • CHIEF COMMERCIAL OFFICER
10b5-1 Sell
|
2025-10-28 | $79,860 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
REED ELIZABETH E
• Officer • Chief Legal Officer and GC
10b5-1 SellΔOwn -10.0%
2025-09-22
$250,000
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • Chief Legal Officer and GC
10b5-1 SellΔOwn -10.0%
|
2025-09-22 | $250,000 | S | Form 4 |